# A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

> **NCT05381909** · PHASE1 · TERMINATED · sponsor: **BeiGene** · enrollment: 157 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** BGB-24714
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05381909
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-06
- **Primary completion:** 2025-07-25
- **Final completion:** 2025-07-25
- **Target enrollment:** 157 (ACTUAL)
- **Why stopped:** The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381909, "A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT05381909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*